Quasar passes FDA inspection with no 483 findings

Quasar passes FDA inspection with no 483 findings

An FDA inspection was conducted at the Quasar manufacturing facility in Shenzhen, October 31  to November 3, 2016.

This is the second consecutive FDA inspection Quasar passed with ZERO findings (no 483). This result endorses Quasar’s commitment to being a world-class medical device manufacturer.

Consistent with Quasar’s legacy of maintaining high quality standards, we focus on quality throughout the facility, whether in employee training, process development, equipment validations and all phases to manufacturing.

social position

More news

Quasar’s new top-technology production facility

We are happy to announce the opening of our new manufacturing facility in Dongguan, China. The facility is now in the validation phase and will fully operational for mass production during Q1-2018. The new facility is our newest asset in our effort to deliver higher quality and newer technologies for innovative medical device mass production and process-design services.

Quasar passes FDA inspection with no 483 findings

An FDA audit was conducted from October 31 to November 3 at the Quasar manufacturing facility in Shenzhen. This is the second consecutive audit Quasar has passed, by the FDA, and the result with NO findings in non-conformance (no 483) endorses Quasar’s renewed commitment to being a qualified medical device manufacturer. Consistent with Quasar’s legacy of maintaining high quality standards, quality is focused on throughout the entire production process, starting from development, and maintained through all phases to manufacturing.